Free Trial

Intersect ENT (XENT) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
14,512 shs
Average Volume
351,526 shs
Market Capitalization
$954.91 million
P/E Ratio
Dividend Yield
Price Target
XENT stock logo

About Intersect ENT Stock (NASDAQ:XENT)

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.

XENT Stock News Headlines

XENT Historical Data
DexCom (DXCM) Misses Q1 Earnings Estimates
Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
See More Headlines
Receive XENT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Surgical & Medical Instruments
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$106.75 million
Book Value
($2.06) per share


Free Float
Market Cap
$954.91 million
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Thomas A. West (Age 58)
    Pres, CEO & Director
    Comp: $908.97k
  • Mr. Richard A. Meier (Age 62)
    Exec. VP & CFO
    Comp: $621.76k
  • Mr. Patrick A. Broderick (Age 63)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $138.46k
  • Ms. Reyna M. Fernandez
    Chief Human Resource Officer
  • Mr. Drake R. Parker (Age 58)
    Advisor of Strategic Initiatives

XENT Stock Analysis - Frequently Asked Questions

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) announced its quarterly earnings data on Tuesday, November, 2nd. The medical equipment provider reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.06. The medical equipment provider earned $24.40 million during the quarter, compared to the consensus estimate of $29.63 million. Intersect ENT had a negative net margin of 161.94% and a negative trailing twelve-month return on equity of 709.52%.

What is Thomas West's approval rating as Intersect ENT's CEO?

7 employees have rated Intersect ENT Chief Executive Officer Thomas West on Thomas West has an approval rating of 41% among the company's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Intersect ENT own?
This page (NASDAQ:XENT) was last updated on 5/22/2024 by Staff

From Our Partners